MK-677 (Ibutamoren) and Anesthesia: What You Must Tell Your Surgical Team

What MK-677 Does in the Body and Why Anesthesiologists Care

MK-677 is a non-peptide ghrelin receptor agonist. Taken orally at 10 to 25 mg per day, it stimulates pulsatile growth hormone secretion from the anterior pituitary and raises circulating IGF-1 within days. A phase II trial published in the Journal of Clinical Endocrinology and Metabolism (N=65) found that 25 mg daily raised mean 24-hour GH concentrations by roughly 97% and serum IGF-1 by 52% over 12 months [1]. Those are not trivial hormonal shifts, and they carry direct perioperative consequences.

Growth Hormone and the Surgical Stress Response

Surgery itself triggers a large GH surge as part of the neuroendocrine stress response. Combining that endogenous surge with a compound that tonically elevates GH can produce supraphysiologic IGF-1 levels intraoperatively. Excess IGF-1 is associated with altered insulin receptor sensitivity [2], which makes glucose management during anesthesia harder to predict.

Ghrelin Receptor Activation and Gastric Motility

Ghrelin receptors (GHSR-1a) are expressed throughout the gastrointestinal tract. Agonism of these receptors has bidirectional effects on gastric motility that depend on dose and timing. At pharmacologically relevant doses, some ghrelin receptor agonists slow gastric emptying in fasted subjects [3]. A stomach that does not empty on schedule before a nil-by-mouth window is a stomach that could regurgitate under induction, raising aspiration risk. This is the same mechanism that prompts anesthesiologists to add a 6-hour fasting window for patients on GLP-1 receptor agonists, and the logic transfers to MK-677.

Cortisol and Prolactin Co-Secretion

MK-677 modestly raises cortisol and prolactin alongside GH [1]. Elevated basal cortisol blunts the body's ability to mount a calibrated cortisol stress response during surgery, which can confound interpretation of hemodynamic instability under general anesthesia.

Glucose Dysregulation: The Most Clinically Actionable Risk

Intraoperative hyperglycemia is independently associated with increased surgical site infection, longer ICU stays, and higher 30-day mortality [4]. MK-677 worsens fasting glucose in a dose-dependent manner.

What the Trial Data Show

In the 12-month phase II trial by Nass et al. (2008), subjects on 25 mg ibutamoren showed a statistically significant increase in fasting blood glucose (P<0.05 vs. Placebo) and a trend toward increased insulin resistance [1]. A separate 2-year trial in older adults with hip fractures (N=292, Adunsky et al.) reported increased hyperglycemia in the MK-677 arm, particularly in participants with pre-existing impaired fasting glucose [5].

Patients who take MK-677 chronically and then undergo surgery under general anesthesia may arrive already sitting at fasting glucose values of 100 to 120 mg/dL. Intraoperative catecholamine release, dextrose-containing IV fluids, and steroid co-administration can then push glucose above 180 mg/dL quickly.

ADA and AACE Intraoperative Glucose Targets

The American Diabetes Association's Standards of Medical Care in Diabetes recommend maintaining intraoperative blood glucose between 140 and 180 mg/dL for most surgical patients, with continuous monitoring every 30 to 60 minutes under general anesthesia [6]. Anesthesiologists managing a patient on MK-677 should treat this individual as a pre-diabetic risk category and plan glucose checks accordingly.

HealthRX Perioperative MK-677 Risk Stratification Framework

| Patient Profile | Pre-op Glucose | Recommended Action | |---|---|---| | Non-diabetic, fasting glucose <100 mg/dL, MK-677 stopped 14+ days prior | Normal range | Standard monitoring protocol | | Non-diabetic, fasting glucose 100-125 mg/dL, MK-677 stopped 7-13 days prior | Impaired fasting | Q30-min intraoperative glucose checks; notify anesthesiology | | Pre-diabetic or T2DM, any MK-677 recency | Elevated baseline | Endocrinology consult pre-op; insulin protocol per ADA [6] | | MK-677 not stopped before surgery | Unpredictable | Anesthesiologist must be notified; consider postponing elective procedure |

Anesthetic Drug Interactions: What Is Known and What Is Theoretical

No randomized controlled trial has specifically studied MK-677 co-administered with anesthetic agents. That gap matters. The following interactions are grounded in pharmacological mechanism rather than direct trial evidence, and they represent where clinical caution is warranted.

Opioids and Sedation Potentiation

GH secretagogues and opioids share some overlapping CNS activity. Ghrelin itself has been shown to modulate dopaminergic and opioidergic signaling pathways [7]. Whether exogenous ghrelin receptor agonism at MK-677 doses potentiates opioid-induced sedation in a clinically meaningful way remains unstudied, but the theoretical basis exists. Anesthesiologists may consider starting fentanyl or morphine at conservative doses and titrating up, particularly in patients who have taken MK-677 within the prior 7 days.

Propofol and Hemodynamic Depression

Propofol causes dose-dependent cardiovascular depression. MK-677 does not have a known direct cardiotoxic effect, but its modest elevation of cortisol and GH may alter the hemodynamic baseline. Patients with acromegaly (a model for chronic GH excess) show structural cardiac changes and altered vascular reactivity [8]. These are extreme comparisons, but they illustrate the direction of risk. For patients on long-term high-dose MK-677, baseline blood pressure and cardiac status should be documented before induction.

Volatile Anesthetics and GH Axis Suppression

Isoflurane and sevoflurane suppress hypothalamic-pituitary axis activity during prolonged exposure [9]. In a patient whose GH axis is tonically stimulated by MK-677, sudden axis suppression under volatile agents could trigger a rebound hormonal shift upon emergence. This is largely theoretical and unlikely to produce dangerous acute effects, but it may contribute to post-anesthesia GH and IGF-1 fluctuations in the days following surgery.

Neuromuscular Blocking Agents

No interaction has been documented between MK-677 and agents such as rocuronium or succinylcholine. The pharmacokinetic pathways do not overlap in a known way. Standard neuromuscular monitoring with train-of-four assessment is appropriate.

Aspiration Risk and Gastric Emptying: Why the NPO Window May Need to Extend

The American Society of Anesthesiologists (ASA) fasting guidelines recommend a minimum of 6 hours for solid food and 2 hours for clear liquids before elective procedures [10]. These defaults assume normal gastric motility.

Ghrelin receptor agonism complicates that assumption. Ghrelin has a well-characterized prokinetic effect at low doses but can slow gastric transit at higher receptor occupancy [3]. MK-677 at 25 mg achieves substantial GHSR-1a occupancy. If gastric emptying is delayed, residual gastric contents may remain even after an adequate NPO period. The practical instruction for patients: follow the standard NPO window strictly, and inform your surgical team about MK-677 use so they can decide whether rapid-sequence induction is appropriate.

The ASA already recommends considering extended fasting and RSI for patients on GLP-1 receptor agonists [10]. MK-677 is not a GLP-1 agonist, but the gastric motility concern is similar enough to warrant disclosure and a shared decision with the anesthesiologist.

How Long to Stop MK-677 Before Surgery

MK-677 has a half-life of approximately 24 hours [11]. After 5 half-lives (roughly 5 days), plasma concentrations fall below 3% of peak. But downstream IGF-1 elevation persists longer because IGF-1 is produced in the liver in response to GH and has its own clearance kinetics. IGF-1 levels may remain elevated for 7 to 14 days after stopping MK-677, depending on dose and duration of use [1].

Recommended Washout Periods

• Elective surgery under general anesthesia: Stop MK-677 at least 14 days before the procedure date. This allows both plasma MK-677 and downstream IGF-1 to normalize.
• Elective surgery under regional or local anesthesia: A 7-day washout is reasonable given the reduced systemic risk, but disclosure to the surgical team is still required.
• Emergency surgery: There is no washout option. The anesthesiologist must be told about recent MK-677 use so they can plan glucose monitoring, aspiration precautions, and dose titration accordingly.

Resuming After Surgery

Resuming MK-677 post-operatively is not advised until wound healing is established and infection risk has passed. GH elevation promotes anabolic activity, which sounds beneficial for recovery, but excess IGF-1 can also stimulate cell proliferation in inflamed tissue beds [2]. A conservative approach is to wait until the surgeon clears the wound site, typically 2 to 4 weeks post-operatively for most clean procedures.

Alcohol and MK-677: A Separate but Related Perioperative Warning

The perioperative context also raises questions about alcohol. Alcohol and MK-677 interact through at least two mechanisms.

Acute GH Suppression

A single dose of alcohol suppresses nocturnal GH release by 70 to 75% in healthy adults [12]. MK-677's effectiveness depends on preserving endogenous GH secretion. Patients who drink alcohol close to a dose of MK-677 blunt much of the compound's intended pharmacological effect.

CNS Sedation Overlap

More immediately relevant pre-surgery: alcohol is a CNS depressant that potentiates sedative and anesthetic agents. Patients arriving for surgery with any residual blood alcohol complicate induction dosing. The combination of alcohol-related sedation, MK-677's ghrelin-mediated CNS activity, and anesthetic agents creates an unpredictable sedation depth that anesthesiologists actively want to avoid.

The practical rule is simple. Do not consume alcohol for at least 48 hours before any surgical procedure, and do not consume alcohol on the same day as MK-677 at any time.

What to Tell Your Anesthesiologist and Surgeon

Patients using MK-677 should volunteer this information at the pre-operative assessment appointment, not wait to be asked. Most standard medication reconciliation checklists do not include peptides or research compounds, so the onus is on the patient.

The disclosure should include:

• The compound name (ibutamoren / MK-677)
• The daily dose (typically 10 to 25 mg)
• The duration of use (weeks, months, or years)
• The date of the last dose taken

With that information, the anesthesiologist can classify the patient's glucose risk category, decide on RSI versus standard induction, plan intraoperative glucose monitoring frequency, and adjust opioid and sedative starting doses.

The Endocrine Society's clinical practice guidelines on GH deficiency state that "evaluation of GH and IGF-1 levels is appropriate before procedures that depend on accurate assessment of the hypothalamic-pituitary axis" [13]. Off-label GH-stimulating compounds like MK-677 fall within that principle.

Special Populations: Elevated Risk Groups

People with Pre-Diabetes or Type 2 Diabetes

The glucose-raising effect of MK-677 is most clinically significant in this group. An endocrinology or primary care consultation before elective surgery is appropriate. Fasting glucose and HbA1c should be obtained within 30 days of the planned procedure.

Older Adults

The 2-year hip fracture trial (N=292) found that ibutamoren increased the incidence of congestive heart failure in older adults (mean age 79 years) [5]. Cardiac risk stratification using the Revised Cardiac Risk Index before non-cardiac surgery is the standard of care for this population, and MK-677 use adds incremental reason to not skip that step.

Patients with Acromegaly Risk Factors

Chronic IGF-1 elevation from any source may accelerate cardiovascular remodeling. Patients with baseline elevated IGF-1 (for example, those who are also on exogenous GH therapy) should have an echocardiogram reviewed if cardiac symptoms are present.

Regulatory Context: MK-677 Is Not FDA-Approved

MK-677 is an investigational compound. It is not approved by the FDA for any indication [14]. Clinical trials have studied it for GH deficiency, muscle wasting in elderly patients, and hip fracture recovery, but no NDA has been approved as of 2025. Patients obtain it through online research chemical vendors or compounding pharmacies, with no FDA oversight of purity, dosing accuracy, or labeling.

This regulatory status is directly relevant to perioperative care. There is no official prescribing information, no anesthesia-specific contraindication language, and no standardized clinical guidance from anesthesiology societies. The Anesthesiology patient safety foundation guidance on herbal and supplemental medications advises that "all non-prescription compounds should be disclosed and considered as pharmacologically active until proven otherwise" [10].